Alumis Inc. Common Stock
ALMSAlumis Inc. (ALMS) is a biotechnology company focused on developing innovative therapies and solutions primarily within the healthcare and life sciences sectors. The company emphasizes advancing scientific research and technology to address unmet needs in medical treatments, often concentrating on areas such as antibody engineering and advanced therapeutics.
Company News
Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2....
Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0....
Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.
